Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration

Chang, Jee Suk; Kim, Kyung Hwan; Keum, Ki Chang; Noh, Sung Hoon; Lim, Joon Seok; Kim, Hyo Song; Rha, Sun Young; Lee, Yong Chan; Hyung, Woo Jin; Koom, Woong Sub

doi:10.1002/jso.24405

Cited by 15 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the staining intensity was semi-quantitatively scored as 0 (negative), 1 (weak), 2 (intermediate), or 3 (strong). The final immunoreactivity score was defined as the sum of both parameters, and the samples were grouped as having negative (0), weak ( 1 – 2 ), moderate ( 3 ), or strong ( 4 – 6 ) staining. For statistical purposes, only the final immunoreactivity scores of the moderate and strong groups were considered positive, and the other final scores were considered negative.…”

Section: Methodsmentioning

confidence: 99%

“…Due to the lack of effective biomarkers for an early diagnosis, the 5-year survival rate of patients with advanced GC is only 5–15% ( 4 , 5 ). Surgical resection may be the only hope for advanced-stage GC patients, but has a high rate of recurrence ( 6 , 7 ). Therefore, it is imperative to explore novel biomarkers and therapeutic targets that may be helpful in developing targeted therapies for GC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dowregulation of OTX1 attenuates gastric cancer cell proliferation, migration and invasion

Qin¹,

Zhao²,

Sheng³

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

Orthodenticle homolog 1 (OTX1) has previously been revealed to be tightly associated with the development and progression of several human tumors. However, the functional roles and underlying molecular mechanisms of OTX1 in gastric cancer (GC) remain poorly understood. In the present study, we observed that OTX1 was highly expressed in GC tissues compared with adjacent non-tumor tissues based on a large cohort of samples from The Cancer Genome Atlas (TCGA) database. An immunohistochemical analysis indicated that OTX1 levels were increased in tumors that became metastatic compared with those in tumors that did not. This finding was significantly associated with patients who had shorter overall survival times. The knockdown of OTX1 significantly inhibited the proliferation, migration and invasion of SGC-7901 and MGC-803 cells. Furthermore, the knockdown of OTX1 induced cell cycle arrest in the G0/G1 phase and reduced the expression of cyclin D1. In addition, the inhibition of OTX1 led to increased GC cell apoptosis by upregulating cleaved PARP, cleaved caspase-3 and Bax. In conclusion, our data indicated that OTX1 functions as a key regulator in tumor growth and metastasis of GC cells. Thus, OTX1 may be a promising novel target for molecular therapy directed toward GC.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Dowregulation of OTX1 attenuates gastric cancer cell proliferation, migration and invasion

Qin¹,

Zhao²,

Sheng³

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…These factors contribute to a poor prognosis of gastric cancer due to a lack of an effective treatment regimen and correlation data statistics shows the five‐year survival rate of gastric cancer is only 24–25% . Despite recent progress in gastrectomy, chemotherapy and radiotherapy, a large number of all advanced stage gastric cancer patients die of recurrence, even after undergoing curative gastrectomy and adjuvant treatment . To address these issues and to aid in the development of novel targeted therapies for gastric cancer, it is imperative to elucidate the regulatory mechanisms and the molecular alterations modulating tumorigenesis.…”

Section: Introductionmentioning

confidence: 99%

Genome‐wide expression profiling and bioinformatics analysis of deregulated genes in human gastric cancer tissue after gastroscopy

Mao

Zhao

Yin

et al. 2017

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…For locally advanced gastric cancer, the locoregional recurrence rate and distant metastasis rate are still high after D2 radical resection [3][4], leading to poor prognosis of these patients. Therefore, adjuvant chemotherapy after radical surgery is currently recommended for all locally advanced gastric cancer [5].…”

Section: Introductionmentioning

confidence: 99%

Adjuvant SOX Chemotherapy Versus Concurrent Chemoradiotherapy After D2 Radical Resection of Locally Advanced Esophagogastric Junction (EGJ) Adenocarcinoma: Study Protocol for a Randomized Phase III Trial (ARTEG)

Shen

Zhu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Survival benefit of adjuvant radiotherapy for locally advanced gastric cancer following gastrectomy plus D2 lymphadenectomy has always been controversial. Esophagogastric junction (EGJ) adenocarcinoma, which is usually classified as gastric cancer in East Asia, often has a higher locoregional recurrence rate after operation because of its special anatomical characteristics. The aim of this study is to determine whether adjuvant radiotherapy can improve survival of locally advanced EGJ adenocarcinoma after D2 radical resection.Methods: In this phase III, randomized, open label, controlled trial, we plan to recruit 378 patients with Siewert type II and III adenocarcinoma of EGJ, who had undergone transabdominal radical surgery and D2 lymphadenectomy, and were divided into pathological stage IIB to IIIC. All patients will be randomized 1:1 to receive either adjuvant chemotherapy alone (control group) or adjuvant chemotherapy plus chemoradiotherapy (experimental group). Patients allocated to control group will receive eight cycles of S-1 plus oxaliplatin (SOX), while experimental group will receive two cycles of SOX followed by 45-Gy RT combined with S-1 and four additional cycles of SOX. The primary endpoint is three-year disease free survival rate (DFS). The secondary endpoints are three-year overall survival rate (OS), three-year locoregional recurrence free survival rate (LRFS), three-year distant metastasis free survival rate (DMFS), and quality of life (QoL).Discussion: In the past, the adjuvant treatment of EGJ adenocarcinoma need to draw on the experience of esophageal adenocarcinoma or gastric adenocarcinoma. In this study, EGJ adenocarcinoma is considered as an independent disease, and the conclusion will provide evidence for optimal adjuvant therapy of locally advanced EGJ adenocarcinoma after D2 radical resection.Trial registration: ClinicalTrials.gov, NCT03973008. Registered on June 1, 2019.

show abstract

Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration

Cited by 15 publications

References 26 publications

Dowregulation of OTX1 attenuates gastric cancer cell proliferation, migration and invasion

Dowregulation of OTX1 attenuates gastric cancer cell proliferation, migration and invasion

Genome‐wide expression profiling and bioinformatics analysis of deregulated genes in human gastric cancer tissue after gastroscopy

Adjuvant SOX Chemotherapy Versus Concurrent Chemoradiotherapy After D2 Radical Resection of Locally Advanced Esophagogastric Junction (EGJ) Adenocarcinoma: Study Protocol for a Randomized Phase III Trial (ARTEG)

Contact Info

Product

Resources

About